Patents Assigned to CELLBION CO., LTD.
  • Patent number: 11027029
    Abstract: The present invention relates to a peptide thiourea derivative, a pharmaceutically acceptable salt thereof, a radioisotope labeled compound comprising the same, and a pharmaceutical composition for treating or diagnosing prostate cancer comprising the same as an active ingredient. The peptide thiourea derivative of the present invention is excellent in stability in human serum when it is administered in vivo and not only binds well to PSMA expressed in prostate cancer but also inhibits excellently PSMA at a low concentration. Besides, the derivative of the invention has a high water-solubility and can be excreted through the kidney not through the bile passage so that a clear image of the tumor region of prostate cancer can be obtained. Therefore, the derivative of the present invention can be effectively used as a pharmaceutical composition for treating and diagnosing prostate cancer.
    Type: Grant
    Filed: November 9, 2016
    Date of Patent: June 8, 2021
    Assignee: Cellbion Co., Ltd
    Inventors: Jae Min Jeong, Sung-Hyun Moon, Yun-Sang Lee
  • Publication number: 20180339071
    Abstract: The present invention relates to a peptide thiourea derivative, a pharmaceutically acceptable salt thereof, a radioisotope labeled compound comprising the same, and a pharmaceutical composition for treating or diagnosing prostate cancer comprising the same as an active ingredient. The peptide thiourea derivative of the present invention is excellent in stability in human serum when it is administered in vivo and not only binds well to PSMA expressed in prostate cancer but also inhibits excellently PSMA at a low concentration. Besides, the derivative of the invention has a high water-solubility and can be excreted through the kidney not through the bile passage so that a clear image of the tumor region of prostate cancer can be obtained. Therefore, the derivative of the present invention can be effectively used as a pharmaceutical composition for treating and diagnosing prostate cancer.
    Type: Application
    Filed: November 9, 2016
    Publication date: November 29, 2018
    Applicant: CELLBION CO., LTD.
    Inventors: Jae Min Jeong, Sung-Hyun Moon, Yun-Sang Lee
  • Patent number: 9925284
    Abstract: The present invention relates to a nanoparticle having a linker connected to a long alkane or alkene chain, and a method for preparing the nanoparticle. The alkyl chain of C10-30 introduced with a ligand of the present invention can be coated on a hydrophobic nanoparticle through a noncovalent bond, enabling easy introduction of various ligands to the nanoparticle, and the nanoparticle having various functional groups prepared using the method can be applied to fluorescent detection, MRI, raman spectroscopy, optical detection, PET, SPECT, or gamma image device, and the ligand of the visualization agents can be modified to be used for new vessels detection, cancer cell detection, immunocyte detection, hepatocyte detection, cell death detection, and gene detection.
    Type: Grant
    Filed: January 31, 2012
    Date of Patent: March 27, 2018
    Assignee: CELLBION CO., LTD.
    Inventors: Jae Min Jeong, Young Kyoung Lee, Dong Soo Lee, June-Key Chung, Myung Chul Lee